Literature DB >> 7010916

Enzymecytochemistry and immunohistochemistry in monoclonal gammopathy and reactive plasmacytosis.

P Johansen, M K Jensen.   

Abstract

Peripheral blood smears and bone-marrow smears from 29 patients with malignant M-components (25 with multiple myeloma and 4 with malignant lymphoma), 13 patients with benign monoclonal gammopathy (BMG), and 20 patients with polyclonal reactive plasmacytosis were examined by leucocyte alkaline phosphatase score (LAP-score) and by acid phosphatase score in plasma cells from bone-marrow smears. Furthermore, tissue sections from marrow biopsies from all patients were examined by the three-layer unlabelled immunoperoxidase technique to detect cytoplasmic immunoglobulin. The LAP-score was significantly higher in patients with malignant M-components than in patients with BMG and also higher in IgA and IgG myeloma than in IgA and IgG BMG, but the latter difference was not significant. Furthermore, a significant positive correlation between paraprotein concentration and LAP-score was found in multiple myeloma. Acid phosphatase score in plasma cells showed no clear distinction between multiple myeloma and BMG. Immunohistochemical examination showed a distinct monoclonal pattern in both multiple myeloma and BMG, allowing identification of the M-component which in all cases corresponded to the M-component detected by serum examination. Cells producing immunoglobulin classes not matching the M-component were more rare in multiple myeloma than in BMG, but the difference between the two conditions was quantitative and allowed no clear distinction.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7010916     DOI: 10.1111/j.1699-0463.1980.tb02509.x

Source DB:  PubMed          Journal:  Acta Pathol Microbiol Scand A        ISSN: 0365-4184


  1 in total

1.  Use of leucocyte alkaline phosphatase (LAP) score in differentiating malignant from benign paraproteinaemias.

Authors:  G Majumdar; M Hunt; A K Singh
Journal:  J Clin Pathol       Date:  1991-07       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.